CVS vs SLN: fair value comparison
CVS Health Corporation and Silence Therapeutics plc · Updated 2026-10-19
SLN has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, CVS currently ranks higher by quality score.
| CVS | SLN | |
|---|---|---|
| Verdict | Fairly valued | No estimate yet |
| Last price | $86.16 | $8.68 |
| 12-month range | $70.08–$110.60 | $4.30–$15.43 |
| Rank by discount to fair value | #59 of 108 Healthcare | — |
| Rank by quality score | #212 of 301 Healthcare | #213 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Moderate | Low |
| Margin trend | Stable | Expanding |
| Revenue growth | Modest | Declining |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | — | Mixed |
| DCF cross-check | Overvalued | — |
| 52-week position | The lower-middle quarter | The lower-middle quarter |
Full single-stock breakdowns: CVS fair value analysis · SLN fair value analysis